FDA Releases Guidance Document on Human Factors Information in Marketing Submissions - In Compliance Magazine
FDA released a guidance document on human factors information in marketing submissions, affecting drug and biologic manufacturers. The guidance clarifies expectations for including human factors data in NDAs, ANDAs, and BLAs to ensure safe and effective use.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) submitting marketing applications to FDA. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately for new submissions; existing submissions under review may need to supplement with HF data if requested by FDA.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued a final guidance detailing when and how to include human factors (HF) information in marketing submissions, including study design, data analysis, and reporting requirements.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) submitting marketing applications to FDA.
What you must do
Review the guidance and assess whether your current or planned submissions need HF data. Update submission plans to incorporate HF studies if applicable.
Deadline
Immediately for new submissions; existing submissions under review may need to supplement with HF data if requested by FDA.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness